Corporate Presentation August 2016
Presentation

ASH 2015 Investor and Analyst Event
Presentation

ASH 2014 Investor and Analyst Event
Presentation

 

2015 Annual Report
Download here

 

Derivative Lawsuit Settlement Information
Download here

 
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
08/03/16Geron Corporation Reports Second Quarter 2016 Financial Results and Recent EventsPrinter Friendly Version
07/27/16Geron Announces Conference Call to Discuss Second Quarter 2016 Financial ResultsPrinter Friendly Version
07/13/16Geron Announces Issuance of U.S. Patents Related to ImetelstatPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$2.70
Change (%) Stock is Up 0.03 (1.12%)
Volume1,260,448
Data as of 08/26/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7700
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)